| ￥1200 | |
| A04202-50 | |
|
|
|
|
|
|
|
|
|
| Specificity | This product is specific to CCL4 |
| Host Species | Rabbit |
| Immunogen | A synthesized peptide derived from human CCL4 |
| Species Reactivity | Human; Mouse |
| Conjugate | Unconjugated |
| Working concentrations for specific applications should be determined by the investigators. The appropriate concentrations may be affected by secondary antibody affinity, antigen concentration, the sensitivity of the method of detection, temperature, the length of the incubations, and other factors. The suitability of this antibody for applications other than those listed below has not been determined. The following concentration ranges are recommended starting points for this product. | |||||||||
|
|||||||||
| Form | Liquid |
| Storage Buffer | Supplied in 10mM phosphate buffered saline , pH 7.4, 150mM sodium chloride, 0.05% BSA, 0.02% sodium azide and 50% glycerol. |
| Storage Instructions | Store at -20°C. This product is stable for 1 year upon receipt, when handled and stored as instructed. |
| Purification | Affinity-chromatography |
| Isotype | Rabbit IgG |
| Clonality | Monoclonal |
Western blot analysis of CCL4/MIP1 beta expression in (1) THP-1 cell lysate; (2) THP-1 cell treated with PMA+LPS+Brefeldin A. »
| Target Background | Monokine with inflammatory and chemokinetic properties. Binds to CCR5. One of the major HIV-suppressive factors produced by CD8+ T-cells. Recombinant MIP-1-beta induces a dose-dependent inhibition of different strains of HIV-1, HIV-2, and simian immunodeficiency virus (SIV). |
| Synonyms | ACT2; G-26; HC21; LAG1; LAG-1; MIP1B; SCYA2; SCYA4; MIP1B1; AT744.1;MIP-1-beta; |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
